 |
| January 15, 2016 |
| Preventive care: Why the Executive Health Program at Lahey Hospital is Working |
| The best way to contain the rising healthcare cost is preventive medicine. Many Preventive Care programs have been established but do these programs catch diseases early enough in order to intervene resulting in a positive outcome, and provide a positive patient experience in order to maintain patient compliant? Read more |
| |
| To download a newsletter pdf, click here. |
| |
| February 15, 2016 |
Five Important Reasons Why Product Adoption Must Be Incorporated into Product Development |
| When we are developing a product, there is always a solution to a critical problem that we are trying to deliver. In the Life Sciences sector, that would result in reducing morbidity or mortality and increasing the quality of life for patients, or making life easier for physicians, depending on the problem and its solution. Read more |
| |
| To download a newsletter pdf, click here. |
| |
| March 2016 |
| New Legislation Regarding Pharmaceutical Pricing |
| The rising cost of healthcare is due to people living longer and the discovery of more advanced technologies. These advanced technologies require longer Research & Development times, much more rigorous regulatory processes and more costly manufacturing processes, resulting in higher costs of drugs. Read more |
| |
| To download a newsletter pdf, click here. |
| |
| April 2016 |
| Medical Informatics World Conference Highlights |
| Last year, the main theme of the Medical Informatics Conference focused on incorporating electronic medical records (EMRs) to deliver better care for patients and to make life easier for physicians, while at the same time solving interoperability. However, incorporating EMRs is a very difficult task, as outlined by our keynote speakers. This year’s theme focused on cultural change for innovation, first by way of coordinated care, then with technology (EMRs), which will automatically follow and achieve better healthcare outcomes. Here is a summary of some of the keynote speakers. Read more |
| |
| To download a newsletter pdf, click here. |
| |
| May 2016 |
| Paid to Go on Vacation and Get a Good Night’s Rest? |
| This all started back in 2012 when FullContact, a Denver‐based software provider company, offered their employees a $7,500 bonus to go on vacation, on top of their normal vacation pay. Yes, you are reading this correctly. The company’s CEO and founder Bart Lorang calls it a “paid, paid vacation.” Read more |
| |
| To download a newsletter pdf, click here. |
| |
| June 2016 |
| 2016 Translational Imaging Symposium Highlights |
| Scientists have been trying to understand Neurodegenerative diseases; Alzheimer’s (AD), Parkinson’s Disease (PD) and Huntington’s Disease (HD) for decades and while they have made some progress, they are a long ways from finding a treatment for AD. What do we know so far? Read more |
| |
| To download a newsletter pdf, click here. |
| |
| July 2016 |
| Why is Chimeric Antigen Receptors T cell (CART) Therapy a “Hot Topic” Today? |
| Immuno‐oncology (IO) is the buzz word today and it has everyone doing IO research. There are many different types of IO and CAR‐T is one of the cellular therapies. Why are IO and CAR‐T buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months which according to oncologist was a lot back then because the mortality rate in most cancers was 100%. Read more |
| |
| To download a newsletter pdf, click here. |
| |
| August 2016 |
| Why is CAR-T Therapy a Hot Topic Today? – Part 2 |
| Last month, I covered: 1) The types of immuno‐oncology (IO) therapy; 2) Roadblocks to cellular therapies; 3) What are CAR‐T cells and how do they work; and 4) How well does CAR‐T therapy works. If you haven’t had a chance to read it, click here. This month, I will cover: 1) What is the side effect profile; 2) Why CAR‐T therapies will be expensive; 3) Does CAR‐T therapies justify the cost? and 4) Questions still facing the CAR field? Read more |
| |
| To download a newsletter pdf, click here. |
| |
| September 2016 |
| Five (5) Must-Dos That Create Success in the (Connected) Wearable Health Device Market |
| It is projected that the demand for connected wearable devices or monitoring systems will grow from $123 billion (2015) to $612 billion globally in 2024, with 39% of the market share coming from North America, according to a new report by Grand View Research. The demand for these devices is growing for four (4) main reasons: Read more |
| |
| To download a newsletter pdf, click here. |
|
| October 2016 |
| The Real Story Behind the Price of the EpiPen_Oct. 2016 |
| Mylan has been in the hot seat for their pricing on EpiPen. Congress has made it a mission to put more pressure on the company when a number of senators from the Senate Finance Committee sent a letter to the Center for Medicare and Medicaid Services (CMS) Inspector General inquiring whether or not Mylan manipulated the Medicaid Drug Rebate Program (MDRP) by classifying EpiPen as a generic drug, when it is in fact not. Read more |
|
| To download a newsletter pdf, click here. |
|
| November 2016 |
| The Economics of Pharmaceutical Pricing: The Supply Chain |
| Last month I covered the “The Real Story Behind the Pricing of the EpiPen.” In that article, I mentioned that pharmacy retail prices consist of the manufacturer’s price plus all the middlemen prices that it takes to get the product from the manufacturer to the customer. This model is the same for consumer products and the customer price will vary just as a bottle of water might cost $1 in the grocery store, but $1.75 at a convenience store and $5 in a hotel room mini-bar. Read more |
|
| To download a newsletter pdf, click here. |
|
| December 2016 |
| The First Human to Receive the CRISPR, Gene Editing Therapy |
| The race to be the first country to use the CRISPR, gene editing tested in humans is official. Last month, it was reported that Lu You, an oncologist at Sichuan University in Chengdu, China injected the first patient with a PD‐1 knockout engineered T‐cells, using the CRISPR‐Cas9 for an aggressive form of metastatic non‐small cell lung cancer, in a phase I dose escalation clinical trial at West China Hospital, Chengdu. Read more |
|
| To download a newsletter pdf, click here. |
